12.03.2019 aap Implantate AG  DE0005066609

DGAP-News: aap Implantate AG: Postponement of publication of annual accounts 2018


DGAP-News: aap Implantate AG / Key word(s): Annual Results
aap Implantate AG: Postponement of publication of annual accounts 2018

12.03.2019 / 16:44
The issuer is solely responsible for the content of this announcement.

The Management Board of aap Implantate AG ("aap") continues to consistently pursue the strategy to develop aap into a sustainably growing pure player in trauma and to unlock the inherent value of the promising and innovative product and technology base.

In implementing this strategy new developments and temporal shifts occurred in recent months, which require an evaluation and decision on various issues by Management Board and Supervisory Board. As individual decisions within this upcoming evaluation could have to be considered in the annual and consolidated accounts 2018, the company decided to postpone the publication of the annual financial statements 2018 (HGB) and the consolidated financial statements 2018 (IFRS) to 30 April 2019. aap will report on possible developments within this process again after Management Board and Supervisory Board have jointly taken decisions or terminated the evaluation of the topics by other means.


Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin; Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de

12.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

End of News DGAP News Service

786607  12.03.2019 


Die wichtigsten Finanzdaten auf einen Blick
  2013 2014 2015 2016 2017 2018 2019e 2020e
Umsatzerlöse1 28,57 31,59 12,28 10,49 10,90 10,78 11,74 0,00
EBITDA1,2 7,00 2,27 -6,80 -7,89 -6,21 -6,41 -5,50 0,00
EBITDA-Marge3 24,50 7,19 -55,37 -75,21 -56,97 -59,46 -46,85 0,00
EBIT1,4 0,72 -0,05 -9,03 -10,18 -7,99 -8,13 0,00 0,00
EBIT-Marge5 2,52 -0,16 -73,53 -97,04 -73,30 -75,42 0,00 0,00
Jahresüberschuss1 0,58 -0,45 -9,54 -9,33 -8,94 -7,67 0,00 0,00
Netto-Marge6 2,03 -1,42 -77,69 -88,94 -82,02 -71,15 0,00 0,00
Cashflow1,7 3,55 -2,95 -2,27 -7,20 -5,43 -5,92 0,00 0,00
Ergebnis je Aktie8 -0,08 -0,01 -0.17 0,47 -0,31 -0,27 -0,55 -0,09
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Mazars

aap Implantate
WKN Kurs in € Einschätzung Börsenwert in Mio. €
506660 0,497 15,94
KGV 2021e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 9,67 0,000 -9,94
0,47 - 1,36 -2,259
Dividende '19 in € Dividende '20e in € Div.-Rendite '19e
in %
0,00 0,00 0,00 Verschoben
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
Mai 2020 14.08.2020 14.11.2019 30.06.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-5,51% -12,81% 33,60% -48,97%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu aap Implantate AG  ISIN: DE0005066609 können Sie bei DGAP abrufen

Medtech , 506660 , AAQ , XETR:AAQ